The first BCMA-targeted CAR-T cell therapy for second-line treatment of multiple myeloma has been approved by the
About the immunotherapy
Ciltacabtagene autoleucel is an autologous T-cell immunotherapy. When the cilta-cel CAR protein binds to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells,
"The expanded label of CARVYKTI has the potential to transform the treatment paradigm for multiple myeloma by providing patients and physicians with a personalised immunotherapy that can be used earlier in the treatment regimen," commented
Basis of the approval of the CAR-T therapy
The data demonstrated that CARVYKTI offered statistically significant improvement of progression-free survival compared to two standard of care treatment regimens: pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).
"This expanded FDA approval for cilta-cel will allow a wider patient population to access this novel therapy earlier in the course of their treatment," according to Dr
The benefit of the cilta-cel infusion was observed when compared to standard of care continuous therapy in patients who relapsed after one to three prior treatments,
FDA approves Carvykti for patients with multiple myeloma
The post Innovative personalised immunotherapy approved for multiple myeloma appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source